AUT 00206

Drug Profile

AUT 00206

Alternative Names: AUT00206

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Autifony Therapeutics; University of Manchester; University of Newcastle upon Tyne
  • Class Antipsychotics
  • Mechanism of Action Shaw potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 01 Aug 2016 Autifony Therapeutics in collaboration with University of Manchester and Kings College London plans phase Ib trials in Schizophrenia in the United Kingdom
  • 01 Aug 2016 Autifony Therapeutics completes a phase Ia trial in Schizophrenia (In volunteers) in United Kingdom (NCT02589262)
  • 15 Mar 2016 Autifony Therapeutics initiates enrolment in a phase Ib trial in Healthy volunteers in United Kingdom (EudraCT2016-000216-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top